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Classification of Diseases; ICD-O-3: International Classification of Diseases for Oncology; 
RER: relative excess risk; RR: relative risk; SIR: standardised incidence ratio; SPN: 
subsequent primary neoplasm; STS: soft-tissue sarcoma; WT: Wims tumour. 
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Abstract 
 
Background: Survivors of childhood cancer are at risk of subsequent primary neoplasms 
(SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains 
uncertain. We investigated risks of specific digestive SPNs within the largest available cohort 
worldwide.  
Methods: The PanCareSurFup cohort includes 69,460 five-year survivors of childhood 
cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using 
standardised incidence ratios (SIRs), absolute excess risks, and cumulative incidence.  
Results: 427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) 
were diagnosed in 413 survivors. Wims tumour (WT) and Hodgkin lymphoma (HL) survivors 
were at greatest risk (SIR=12.1;95%CI:9.6-15.1; SIR=7.3;95%CI:5.9-9.0, respectively). The 
cumulative incidence increased the most steeply with increasing age for WT survivors, 
reaching 7.4% by age 55 and 9.6% by age 60 years (1.0% expected based on general 
population rates). Regarding colorectal SPNs, WT and HL survivors were at greatest risk; 
both 7-times that expected. By age 55 years, 2.3% of both WT (95%CI:1.4-3.9) and HL 
(95%CI:1.6-3.2) survivors had developed a colorectal SPN—comparable to the risk among 
members of the general population with at least 2 first-degree relatives affected. 
Conclusions: Colonoscopy surveillance before age 55 is recommended in many European 
countries for individuals with a family history of colorectal cancer, but not for WT and HL 
survivors despite a comparable risk profile. Clinically, serious consideration should be given 
to the implementation of colonoscopy surveillance whilst further evaluation of its benefits, 
harms and cost-effectiveness in WT and HL survivors is undertaken. 
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What is already known about this subject? 
Survivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs) including 
digestive SPNs. Increasing number of survivors are now reaching their forties and beyond, 
but the risk of developing specific digestive SPNs, such colorectal, liver, stomach and 
pancreas, beyond age 40 years remains uncertain.  
 
What are the new findings? 
The cumulative incidence of developing any digestive SPN for WT survivors reaches 7.4% 
by age 55 years and 9.6% by age 60 years. The cumulative incidence for colorectal SPNs 
for both WT and HL survivors is 2.3% by age 55; which is comparable to the risk among 
members of the general population with at least 2 first-degree relatives affected by colorectal 
cancer and for whom in many countries colonoscopy surveillance is recommended.  
 
How might it impact on clinical practice in the foreseeable future? 
This study provides evidence that should aid the development of international guidelines for 
surveillance of colorectal cancer among survivors of childhood cancer. Although 
implementation of colorectal cancer surveillance would require evaluation of its benefits, 
harms and cost-effectiveness, the high risks identified in this study suggest that, if not 
already, in most countries colonoscopy surveillance among childhood WT and HL survivors 
should be seriously considered. 
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Introduction 
Over the last few decades five-year survival after childhood cancer has increased 
substantially and is currently over 80% [1]. However, survivors of childhood cancer are at 
risk of long-term adverse health conditions, including subsequent primary neoplasms (SPNs) 
[2–5]. Although the median age of survivors is currently around thirty, an increasing number 
of survivors are now reaching their forties and beyond. Hence it is important to investigate 
among survivors the excess risks of cancers that occur most frequently beyond age 40 
years in the general population, such as cancers of the digestive system [6]. Survivors of 
childhood cancer may be at excess risk of developing such digestive SPNs due to previous 
radiotherapy given involving the abdomen or treatment with specific chemotherapeutic 
agents [7–9]. Previous work has shown that digestive cancers contribute nearly 20% to the 
total excess risk of SPNs observed beyond age 40 in survivors of childhood cancer [3]. Even 
a small increased relative risk compared to the general population sustained into old age 
could lead to a considerable excess numbers of survivors developing a digestive SPN. 
Quantification of the risks would aid in identifying those survivors at highest risks and in 
estimating the number of digestive SPNs that could potentially be prevented, through for 
example surveillance. Clearly, there is a need for large scale studies to quantify the risks of 
digestive SPNs, however, to our knowledge, most studies conducted thus far lacked 
statistical power to satisfactorily address the very long-term risks of digestive SPNs [2–4,7–
11]. For example, the largest cohort study to date not included in the current study included 
14,358 5-year survivors of childhood cancer and 45 digestive SPNs, of which 14 occurred 
beyond age 40 years [7]. 
The principal objective of this largest-ever cohort study was to investigate the risks of 
developing SPNs in specific sites of the digestive system—including colorectal, liver, 
stomach, and pancreas SPNs—among 5-year survivors of childhood cancer beyond age 40 
years. The current study used data from a large-scale Pan-European cohort of nearly 70,000 
5-year survivors of childhood cancer with 427 observed digestive SPNs, of which 230 
occurred beyond age 40 years. 
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Methods 
 
PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies 
(PanCareSurFup) 
PanCareSurFup is a consortium of 16 European institutions in 12 countries established in 
February 2011 and funded by the 7th Framework Programme of the European Commission 
(www.pancaresurfup.eu)[12,13]. The overall aims of the PanCareSurFup consortium are: (i) 
to conduct studies into long-term complications of treatment for cancer, (ii) to establish 
guidelines for clinical follow-up of survivors, (iii) and to disseminate the results and provide 
training and workshops for stakeholders. PanCareSurFup is the largest ever collaborative 
study undertaken to comprehensively investigate specific long-term adverse health 
outcomes among survivors of childhood and adolescent cancer [14]. One of the principal 
objectives of PanCareSurFup was to estimate the risks of developing SPNs among five-year 
survivors of a cancer diagnosed under age 20 years [15,16]. A pooled cohort of survivors of 
childhood cancer was established using data from 13 different sub-cohorts—ascertained 
from cancer registries or major treatment centres—across 12 countries within Europe, 
including: Great Britain, Norway, Sweden, Finland, Denmark, Iceland, France, Switzerland, 
Hungary, Slovenia, Italy, and the Netherlands (eTable 1). Ethical approval was not obtained 
specifically for this study as it involved pooling of non-identifiable data. Ethical approval was 
obtained within the country of origin of each contributing sub-cohort separately. 
 
Childhood cancer classification 
Site and type of childhood tumour were coded using a variety of different tumour 
classification systems across the sub-cohorts provided by the countries; however, for the 
pooled cohort all tumour classification codes were converted into the third revision of the 
International Classification of Diseases for Oncology (ICD-O-3) using the Cancer Registry 
Tools program developed by the International Agency for Research on Cancer and the 
International Association of Cancer Registries [17]. Individuals were excluded from the 
pooled cohort if: a) the first primary diagnosis was myelodysplastic syndrome, Langerhans 
cell histiocytosis, a chronic myeloproliferative or lymphoproliferative disorder or a 
immunoproliferative disease; b) tumour codes were of a non-malignant behaviour code 
except for intra-cranial and bladder tumours and survivors; c) tumour codes were not 
classifiable according to the International Classification of Childhood Cancers (ICCC) (3rd 
revision)[18] (eFigure 1). 
 
Subsequent primary neoplasm ascertainment  
SPNs were ascertained through: linkage with population-based national cancer registries, 
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follow-up clinics, questionnaires, available medical records, linkage with national mortality 
registries, and linkage with health insurance registries (eTable 1). SPNs were classified by 
digestive site using the International Classification of Diseases (ICD) (eTable 2). Potential 
digestive SPNs were only included if the behaviour code was malignant (ICD-O behaviour 
code: 3). SPNs were validated principally using pathology reports and occasionally other 
definitive diagnostic reports. 
 
Statistical Analysis 
The period at risk of developing a SPN commenced five years from childhood cancer 
diagnosis until the first occurrence of: death, loss-to-follow-up, or study exit date. Survivors 
lost to follow-up were censored at last known date alive. Multiple SPNs per survivor were 
permitted in all analyses unless otherwise specified to avoid bias because the general 
population cancer registration rates include multiple primaries. Standardised incidence ratios 
(SIR) were calculated as the ratio of observed to expected number of digestive neoplasms 
[19]. Expected numbers were estimated by accumulating person-years at risk within country, 
sex, age, and calendar year specific strata and multiplying by the corresponding digestive 
neoplasms incidence rates in the general population. General population incidence rates for 
each specific digestive neoplasm site by country, sex, age (5-year bands), and calendar 
year (1-year bands) were obtained from the Cancer Incidence in Five Continents and the 
European Cancer Observatory database [20,21]. Since cancer site-specific neoplasm rates 
do not exist for Hungary these were estimated by dividing age, sex and calendar year 
specific cancer incidence rates from the neighbouring country Slovakia by corresponding 
Slovakian mortality rates and then multiplying these by available Hungarian mortality rates 
[22]. Absolute excess risks (AERs) were calculated as the observed minus expected number 
of specific digestive neoplasms, divided by the number of person-years at risk, multiplied by 
100,000. Multivariable Poisson regression models were fitted to estimate the relative risk 
(RR) and the relative excess risk (RER) of each digestive SPN taking into account the 
simultaneous effect of the factors: sex, type of childhood cancer, country, age at diagnosis, 
era of diagnosis, and attained age [23]. Relative risks (RR) may be interpreted as the ratio of 
SIRs, adjusted for relevant co-factors fitted. Similarly, relative excess risks (RER) may be 
interpreted as the ratio of AERs, adjusted for relevant co-factors fitted. Negative binomial 
regression was used when the Poisson regression model fit showed signs of overdispersion 
[24]. 
Cumulative incidence of the first digestive SPN was estimated by treating death as a 
competing risk [25,26] and compared to the expected cumulative incidence derived from 
general population incidence rates by the conditional (Ederer II) method [27]. For colorectal 
cancer, the cumulative incidence in survivors was also compared to the expected cumulative 
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incidence from subgroups of the general population known to have an increased risk of 
colorectal cancer and for whom undergoing colonoscopy surveillance from an early age is 
recommended in many countries; i) those with at least 2 first-degree relatives affected by 
colorectal cancer and ii) those with at least one first-degree relative affected. These 
expected incidences were estimated using age-specific RRs of colorectal cancer for these 
subgroups compared to the general population from published meta-analyses and 
multiplying the age-specific RRs to the corresponding age-specific colorectal cancer 
incidence rates from the relevant national general population [28,29]. 
Tests for linear trend for a specific factor (e.g. attained age) were performed by using 
a likelihood-ratio test comparing the deviance of a model containing the factor of interest as 
a continuous variable (e.g. 1,2,3,4) to the deviance of a model without this factor. Statistical 
significance for all analyses was defined as a two-sided P-value of less than 0.05. All 
analyses were carried out in Stata 16 (StataCorp, College Station, Texas). 
 
Patient and Public Involvement 
The PanCare network is a multidisciplinary pan‐European network of professionals, 
survivors and their families. Members of PanCare meet biannually and the work in this 
manuscript has been presented at these meetings and has benefited from feedback from 
survivors and their families. 
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Results 
 
Cohort Characteristics 
Following five-year survival from childhood cancer diagnosis, 69,460 survivors in the pooled 
cohort were followed up for 1,264,624 person-years with a mean and median follow-up of 
18.2 and 16.3 years, respectively (range: 5-70 years). Loss-to-follow-up did not exceed 6% 
(eTable 1). Over the follow-up period, 427 digestive SPNs were diagnosed in 413 survivors 
with 12 survivors diagnosed with two digestive SPNs and one survivor with three digestive 
SPNs. Digestive SPNs were most frequently diagnosed after Hodgkin's lymphoma (HL) 
(N=85) and Wilms tumour (WT) (N=77) (Table 1). From the 427 digestive SPNs, 214 
(50.1%) were colorectal, 62 (14.5%) liver, 48 (11.2%) stomach, 44 (10.3%) pancreatic, 33 
(7.7%) small intestine, 19 (4.4%) oesophageal, and 7 (1.6%) gall bladder cancer. 
 
Any digestive SPN 
Overall, survivors of childhood cancer were more than three times more likely to develop any 
SPN of the digestive system compared to that expected from the general population 
(SIR=3.4; 95%CI: 3.1-3.8), with 24 additional cases of subsequent digestive cancer 
observed per 100,000 person-years (Table 2). The SIR decreased significantly with 
increasing attained age (Ptrend<0.001), but even at age 40-49 and age 50+ years it was still 
3.7-fold and 1.6-fold that expected, respectively (Table 3). In contrast, the AER increased 
significantly with attained age, reaching up to 79 excess SPNs per 100,000 person-years 
after age 50 years (Ptrend<0.001). These patterns in SIRs and AERs with attained age were 
confirmed in multivariable analyses (eTable 3). No significant variation in RRs and RERs 
with era of diagnosis was observed after adjustment for attained age in multivariable 
analyses (Multivariable Ptrend ≥ 0.30) (Table 3 & eTable 3). With regard to the risk by 
childhood cancer type, WT and HL survivors were at greatest risk of developing a digestive 
SPN compared to expected (SIR=12.1; 95%CI: 9.6-15.1 and SIR=7.3; 95%CI: 5.9-9.0, 
respectively) (Table 3). Although to a lesser extent, each other specific type of childhood 
cancer—except bone sarcoma—was also at a significantly increased risk of developing a 
digestive SPN. Of all childhood cancer types, the cumulative incidence for WT survivors 
increased the most steeply with increasing attained age; by age 30 years 0.4% (95%CI: 0.2, 
0.6) had developed a digestive SPN, but by age 50 years this percentage was already 4.2% 
(95%CI: 3.1, 5.6), 7.4% (895%CI: 5.5, 9.8) by age 55, and reached 9.6% (95%CI:6.7, 13.2) 
by age 60 years (Figure 1).  
 
Colorectal SPN 
Survivors experienced three times the number of colorectal cancers compared to that 
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expected from the general population (SIR=3.0; 95%CI: 2.6-3.4), with 11 excess colorectal 
cancers per 100,000 person-years (Table 2). The SIR was significantly greater at younger 
ages at diagnosis (Ptrend<0.001) (Table 3)—this trend was confirmed in multivariable 
analyses (Ptrend =0.001) (eTable 3). Overall, the SIR of developing a colon SPN (SIR=3.4, 
95%CI: 2.9, 4.1) was greater than that of developing a rectum SPN (SIR=2.3, 95%CI: 1.8, 
2.9). In multivariable analyses there was no significant association with era of childhood 
cancer diagnosis after adjustment for confounders, particularly attained age, for both SIR 
and AER (Ptrend≥0.77) (Table 3 & eTable 3). The AER increased significantly with attained 
age, reaching 29 excess colorectal SPNs per 100,000 person-years among those aged at 
least 50 years. Although the AER increased with attained age, 20% of all colorectal SPNs 
still occurred before age 30 years. Compared to the general population, WT and HL 
survivors were at greatest risk of developing a colorectal SPN; both 7-times that expected. 
By age 55 years, 2.3% (95%CI: 1.4, 3.9) of WT survivors and 2.3% (95%CI: 1.6, 3.2) of HL 
survivors had developed a colorectal SPN, similar to the 2.3% experienced by members of 
the general population with at least 2 first-degree relatives affected with colorectal cancer 
(Figure 2). Soft-tissue sarcoma survivors were at similar risk of developing a colorectal SPN 
as members of the general population with at least one first-degree relative affected 
(cumulative incidence =1.3%, 95%CI: 0.7, 2.1) by age 55 years. 
 
Liver SPN  
The overall SIR of developing a liver SPN was 8-fold that expected with an AER that was 4 
per 100,000 person-years, but the AER increased significantly with increasing attained age 
from only 1 under age 20 years to 15 among those aged at least 50 years (Table 3). 
Survivors of WT had the highest risk of developing a liver SPN; 41-fold that expected 
(95%CI: 26.2-64.3), although most other types of childhood cancer also exhibited high SIRs 
(Table 3).  
 
Stomach SPN 
Overall, survivors had 3-times higher risk of stomach cancer than expected (SIR=2.9, 
95%CI: 2.1-3.9), with 2 excess cases per 100,000 person-years in excess of that expected 
(Table 3). Survivors diagnosed in more recent calendar years appeared to be at higher risk 
of developing a stomach SPN than those diagnosed before 1970 (Ptrend=0.04) (eTable 3). 
With regard to childhood cancer type, survivors of WT and HL were at greatest risk relative 
to the general population with SIRs that were nearly 9-fold.  
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Pancreas SPN 
Overall, survivors experienced 3-fold the number of pancreatic SPNs (SIR=3.2; 95%CI: 2.3-
4.2), with 2 excess cases per 100,000 person-years compared to that expected from the 
general population (Table 3). The SIR decreased significantly with increasing attained age, 
but even beyond age 40 years survivors were still at over 2-fold risk compared to that 
expected (SIR=2.3, 95%CI: 1.6-3.4). The risk of developing a pancreatic SPN was greatest 
for survivors of WT and HL at 17-fold and 7-fold compared to that expected, respectively. 
 
Small intestine, oesophagus, and gall bladder SPNs 
The highest SIR of any digestive SPN was observed for SPNs of the small intestine 
(SIR=11.3, 95%CI: 7.8, 15.9) although the AER was relatively modest (AER=2) when, for 
example, compared to the AER of colorectal SPNs (AER=11) (Table 2). The SIR for 
oesophagus SPNs was the lowest of all digestive SPNs (SIR=1.7, 95%CI: 1.0, 2.7). The SIR 
for gall bladder SPNs was non-significant (SIR=2.4, 95%CI: 0.9, 4.9), but only 7 SPNs were 
observed at this site. 
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Discussion 
Main findings 
In this by far the largest-ever cohort study investigating the risks of digestive SPNs in 
survivors of childhood cancer we provide, for the first time, accurate risk estimates of 
specific digestive cancers such as colorectal, liver, pancreas and stomach after age 40 
years. Important findings include that for WT and HL survivors the cumulative incidence of 
developing colorectal cancer exceeds 2% by age 55 and is similar to that observed among 
individuals from the general population with at least 2 first-degree relatives affected by 
colorectal cancer. Other novel findings include the identification of a substantial risk of 
developing any digestive SPN among WT survivors in that by age 60 the cumulative risk is 
nearly 10% where only 1.4% was expected. 
 
Previous studies 
When evaluating the risk of developing any digestive SPNs among all childhood cancer 
survivors combined, the 3.4-fold SIR observed in this study was consistent with SIRs from all  
[3,4,7,11] but one previous study [30]. For colorectal cancer specifically, the SIRs observed 
in the current study were generally also consistent with previous studies [3,7,9–11,30–32]. 
Although previous studies had fewer person-years beyond age 40, SIRs generally also 
decreased and AERs increased with increasing attained age or follow-up [3,30]. The 
identified risks of developing colorectal SPNs, particularly among WT and HL survivors, are 
coherent with a preponderant role of radiation exposure of the abdominal area as 
demonstrated in smaller studies or studies with shorter follow-up [3,7,8,32]. The increased 
risk of developing a colorectal SPN among STS survivors which is similar to the risk of 
individuals from the general population with at least 1 first degree relative has not been 
reported before, but is likely related to abdominal radiation exposure as well as the majority 
of STSs occurred in the abdomino-pelvic area (62%). The risks reported here are likely to be 
an underestimate of the actual risk among those treated with abdominal radiotherapy as not 
all WT, HL and STS survivors included in this study will have been treated with radiotherapy 
to the abdominal area. Although exposure of the abdomen to radiation is likely to be the 
principal risk factor, previous studies among childhood cancer and young HL survivors have 
also demonstrated that exposure to procarbazine and/or cisplatin increases the risk of 
subsequent primary colorectal cancer [7,32]. 
For liver, stomach, and pancreatic SPNs the overall SIRs were all significantly 
elevated, but most previous studies had very few observed numbers of such SPNs 
complicating comparisons of the risks observed between studies [10,11,30,33].To our 
knowledge, no previous study has had sufficient statistical power to satisfactorily investigate 
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the risks of these SPNs by type of childhood cancer. In this study, particularly survivors of 
WT were at substantial risk of developing liver SPNs compared to the general population 
with a 41-fold increased SIR. Although investigation of treatment related factors was not 
feasible here, this substantially increased risk is likely attributable to radiation given for the 
original WT as the liver would most likely have been in the radiation field. Whilst the AER of 
developing stomach cancer was low, very high SIRs (9-fold expected) of stomach cancer 
were observed for survivors of a previous WT and HL. Previous studies among HL survivors 
demonstrated a dose-response with cumulative radiation dose received by the stomach and 
risk of developing stomach cancer [34,35], but to our knowledge no study suggested that 
survivors of a WT were also at substantially increased risk. With regard to pancreatic cancer, 
particularly WT survivors were at a very high risk relative to the general population (17-fold 
increased SIR) and to our knowledge no previous study reported risks for SPNs of the 
pancreas among WT survivors. 
 
Risk by era of diagnosis  
After adjustment for potential confounders in multivariable analyses, particularly with regard 
to attained age, no significant variations in relative or absolute risks were detected by era of 
diagnosis, except for the RR of stomach SPNs. It is important to note that survivors treated 
more recently have not yet reached ages at which in the general population the risks of 
developing digestive neoplasm increases substantially (i.e. beyond age 40 years) and thus 
any inferences with regard to era of diagnosis in relation to the long-term risk of developing a 
digestive SPN are difficult to make. Further follow-up of more recently treated survivors will 
be required to address such questions in the future. 
 
Clinical implications 
Firstly, current North American guidelines for the follow-up of survivors of childhood cancer 
from the Children's Oncology Group suggest any survivor treated with abdominal pelvic 
and/or spinal radiation or total body irradiation should receive colonoscopy surveillance for 
colorectal cancer 5 years after treatment or at age 30 years, whichever occurs last [36]. 
Multitarget stool DNA testing could be considered as an alternative if survivors are not willing 
to undergo colonoscopy. However, these North American guidelines are largely based on 
expert consensus and common European guidelines specifically relating to colorectal cancer 
surveillance do currently not exist. Within the International Guideline Harmonisation Group 
(www.ighg.org) for surveillance of late effects in childhood cancer survivors, the 
development of an international guideline on surveillance of colorectal cancer is a priority 
[37]. The current results should aid in the development of such guidelines in that we provide 
evidence that the risk of developing colorectal cancer increases substantially from age 30 
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years onwards among survivors of WT and HL, in that by age 55 years at least 2% of WT 
and HL survivors had developed a colorectal SPN. Given that this risk exceeds that of 
individuals from the general population with at least 2 first-degree relatives affected—and for 
whom in many countries colorectal cancer screening and surveillance guidelines 
recommend offering colonoscopy before age 55 years [38–40]—serious consideration 
should be given for implementation of colorectal cancer surveillance among WT and HL 
survivors. 
 Secondly, among WT survivors the risk of developing any digestive SPN was 7.4% 
by age 55 and 10% by age 60 years compared to 1% expected by age 60. The SPNs 
accounting for most of this excess risk, in addition to colorectal cancer, were of liver and 
pancreas. Evaluating the potential benefits, harms and cost-effectiveness of surveillance 
options to detect such liver and pancreatic lesions early would be prudent. For example, 
surveillance for hepatocellular carcinoma through regular ultra-sound examinations is 
effective for cirrhosis and hepatitis-B patients in the general population [41]. Whether similar 
surveillance would be effective among WT survivors is, however, unknown and would need 
in-depth evaluation of its benefits, harms and costs before being implemented. 
 
Study limitations 
For the development of international guidelines, information on dose thresholds for 
performing surveillance would be desirable since it currently remains uncertain whether 
survivors treated with lower doses of cumulative radiation to the abdomen or those who 
received total body irradiation would also be at risk and therefore would benefit from 
colonoscopy surveillance or not. The influence of alkylating agents and cisplatin dose 
exposure on the risk of developing colorectal and other digestive SPNs also requires more 
investigation. However, collection of such detailed past treatment exposure for the purpose 
of a cohort study would require obtaining and reviewing medical records and radiotherapy 
treatment charts of all individuals in the entire cohort of nearly 70,000 survivors, which was 
practically not feasible. We are currently in the process of conducting a case-control study 
nested within the current cohort and should be able to address the risks of developing 
colorectal SPNs at the lower end of the radiation dose spectrum and influence of different 
types of chemotherapy exposures. In addition, we will use the relative risk estimates from 
the nested case-control study, together with general population rates of specific digestive 
cancers, to develop absolute risk prediction models for specific digestive SPNs for the 
survivors and thus identify particularly high risk subgroups for whom interventions (e.g. 
colonoscopy surveillance) are more likely to be beneficial and cost-effective. 
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Conclusions 
In conclusion, most childhood cancer survivor groups are at risk of developing a digestive 
SPN, but particularly WT and HL survivors. The risk of developing colorectal cancer among 
WT and HL survivors is similar to individuals from the general population with at least 2 first-
degree relatives affected. In many European countries colonoscopy surveillance before age 
55 years is recommended with such family history, but not for WT and HL survivors despite 
a comparable risk profile. Clinically, serious consideration should be given to the 
implementation of colonoscopy surveillance whilst further evaluation of its benefits, harms 
and cost-effectiveness in WT and HL survivors is undertaken.  
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Table 1. Characteristics of all 69,460 five-year survivors in the PanCareSurFup study and number of subsequent primary 
neoplasm of the digestive system. 
  N (%) digestive SPNa 
all survivors  69460 (100%) 427 (100%) 
sex  male 37738 (54.3%) 274 (64.2%) 
 female 31722 (45.7%) 153 (35.8%) 
childhood  leukaemia 16595 (23.9%) 30 (7.0%) 
cancer type Hodgkin’s lymphoma 6000 (8.6%) 85 (19.9%) 
 non-Hodgkin’s lymphoma 3350 (4.8%) 26 (6.1%) 
 central nervous system tumour 14529 (20.9%) 60 (14.1%) 
 neuroblastoma 3169 (4.6%) 10 (2.3%) 
 retinoblastoma 2578 (3.7%) 13 (3.0%) 
 Wilms’ tumour 4756 (6.8%) 77 (18.0%) 
 bone tumour 3147 (4.5%) 14 (3.3%) 
 soft-tissue Sarcoma 4501 (6.5%) 43 (10.1%) 
 gonadal tumour testis 1664 (2.4%) 10 (2.3%) 
 gonadal tumours ovary 1038 (1.5%) 17 (4.0%) 
 otherb 7770 (11.2%) 35 (8.2%) 
 unclassified 363 (0.5%) 7 (1.6%) 
age at childhood  0-4 22013 (31.7%) 117 (27.3%) 
cancer diagnosis 5-9 14846 (21.4%) 84 (19.6%) 
(years) 10-14 11199 (16.1%) 80 (18.7%) 
 15-19 21402 (30.8%) 147 (34.3%) 
data provider France 3138 (4.5%) 63 (14.8%) 
country Hungary 4885 (7.0%) 17 (4.0%) 
 Italy (population-based)c 7476 (10.8%) 14 (3.3%) 
 Italy (hospital-based)d 1490 (2.1%) 4 (0.9%) 
 Netherlands 6044 (8.7%) 17 (4.0%) 
 Denmark  4840 (7.0%) 31 (7.3%) 
 Sweden 7709 (11.1%) 14 (3.3%) 
 Norway  3783 (5.4%) 11 (2.6%) 
 Finland 6229 (9.0%) 40 (9.4%) 
 Iceland  275 (0.4%) 0 (0.0%) 
 Slovenia  1252 (1.8%) 9 (2.1%) 
 Switzerland  4379 (6.3%) 5 (1.2%) 
 United Kingdom 17960 (25.9%) 202 (47.3%) 
era of  <1970 8993 (12.9%) 178 (41.7%) 
diagnosis 1970-79 13479 (19.4%) 152 (35.6%) 
 1980-89 20900 (30.1%) 78 (18.3%) 
 1990-2008 26088 (37.6%) 19 (4.4%) 
attained  <20 15405 (22.2%) 24 (5.6%) 
age (years) 20-29 18877 (27.2%) 66 (15.5%) 
 30-39 17145 (24.7%) 107 (25.1%) 
 40-49 10969 (15.8%) 124 (29.0%) 
 50+ 7064 (10.2%) 106 (24.8%) 
aA total of 427 digestive SPNs were observed among 413 survivors. 
b”Other” category includes; malignant melanomas (N=1390), thyroid carcinomas (N=1229), other and unspecified carcinomas (N=1111), Burkitt 
lymphoma (N=680), malignant extracranial/extragonadal germ cell tumours (N=421), skin carcinomas (N=386), unspecified lymphomas (N=377), 
hepatoblastoma (N=314), miscellaneous lymphoreticular neoplasms (N=274), nasopharyngeal carcinomas (N=169), renal carcinomas (N=121), other 
peripheral nervous cell tumours (N=91), hepatic carcinomas (N=81), adrenocortical carcinomas (N=70), other specified malignant tumours (N=50), 
unspecified malignant renal tumours (N=35), unspecified malignant hepatic tumours (N=15), other and unspecified malignant tumours (N=956). 
cPopulation-based cohort from the childhood cancer registry of Piedmont region in Italy. 
dHospital-based registry from the Italian Registry of Off Therapy Patients, Genova. 
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Table 2. Standardised incidence ratios and absolute excess risks for specific 
 digestive subsequent primary neoplasms (SPNs) 
SPN Obs Expa SIR (95%CI) AER (95%CI)b 
any digestive 427 124.5 3.4 (3.1,3.8) 24 (21,27) 
colorectal 214 72.5 3.0 (2.6,3.4) 11 (9,13) 
—colon only 144 41.8 3.4 (2.9,4.1) 8 (7,10) 
—rectum only 70 30.7 2.3 (1.8,2.9) 3 (2,4) 
liver 62 7.7 8.1 (6.2,10.3) 4 (3,6) 
stomach 48 16.5 2.9 (2.1,3.9) 2 (2,4) 
pancreas 44 13.6 3.2 (2.3,4.3) 2 (2,3) 
small intestine 33 2.9 11.3 (7.8,15.9) 2 (2,3) 
oesophagus 19 11.0 1.7 (1.0,2.7) 1 (0,1) 
gall bladder 7 3.0 2.4 (0.9,4.9) 0 (0,1) 
aExpected numbers do not add up to total for all digestive SPNs because general population cancer incidence  
reference rates for small intestine, oesophagus, and gall bladder were obtained through ECO; others through CI5. 
bper 100,000 person-years 
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Table 3. Standardised incidence ratios and absolute excess risks for any digestive and colorectal (plus colon and rectum, separately) subsequent primary neoplasm. 
  any digestive colorectal colon only rectum only 
Factor level O SIR (95%CI) AER (95%CI) O SIR (95%CI) AER (95%CI) O SIR (95%CI) AER (95%CI) O SIR (95%CI) AER (95%CI) 
Overall All combined 427 3.4 (3.1,3.8) 24 (21,27) 214 3.0 (2.6,3.4) 11 (9,13) 144 3.4 (2.9,4.1) 8 (7,10) 70 2.3 (1.8,2.9) 3 (2,4) 
Sex Male 274 3.7 (3.3,4.2) 30 (25,35) 134 3.4 (2.9,4.0) 14 (11,18) 90 4.1 (3.4,5.1) 10 (8,13) 45 2.5 (1.9,3.4) 4 (2,7)  
Female 153 3.0 (2.5,3.5) 17 (14,22) 78 2.4 (1.9,3.0) 8 (5,11) 54 2.7 (2.1,3.5) 6 (4,9) 25 1.9 (1.3,2.9) 2 (1,5)  
Pheterogeneity*  0.02 (0.02) <0.001 (<0.001)  0.01 (0.03) 0.01 (0.07)  0.01 (0.08) 0.02 (0.28)  0.27 (0.16) 0.13 (0.10) 
Age at  0-4 116 5.3 (4.4,6.3) 21 (17,27) 52 4.0 (3.1,5.3) 9 (6,13) 37 5.0 (3.6,6.8) 7 (5,10) 15 2.7 (1.7,4.5) 2 (1,5) 
diagnosis  5-9 84 4.6 (3.7,5.7) 24 (18,31) 46 4.2 (3.2,5.7) 13 (9,18) 37 5.9 (4.3,8.2) 11 (7,16) 9 2.0 (1.0,3.8) 2 (0,6) 
(yrs) 10-14 80 3.2 (2.6,4.0) 26 (19,36) 50 3.5 (2.6,4.6) 17 (11,25) 30 3.6 (2.5,5.2) 10 (6,17) 20 3.2 (2.1,5.0) 7 (3,12) 
 15-19 147 2.5 (2.1,2.9) 26 (20,34) 66 1.9 (1.5,2.5) 9 (6,15) 40 2.0 (1.5,2.8) 6 (3,11) 26 1.8 (1.2,2.6) 3 (1,8) 
 Ptrend*  <0.001 (0.01) 0.24 (<0.001)  <0.001 (<0.001) 0.44 (<0.001)  <0.001 (0.01) 0.97 (<0.001)  0.28 (0.13) 0.17 (0.05) 
Era of  <1970 178 2.1 (1.8,2.5) 31 (23,40) 93 1.9 (1.6,2.4) 14 (9,22) 62 2.3 (1.8,2.9) 11 (7,17) 31 1.5 (1.1,2.1) 3 (1,10) 
diagnosis 1970-1979 152 5.8 (4.9,6.8) 36 (29,43) 76 4.9 (3.9,6.2) 17 (13,23) 54 6.2 (4.7,8.1) 13 (9,18) 22 3.3 (2.2,5.0) 4 (2,8) 
 1980-1989 78 6.4 (5.1,8.0) 16 (13,21) 35 4.7 (3.4,6.5) 7 (5,11) 23 5.0 (3.3,7.5) 5 (3,8) 12 4.2 (2.4,7.3) 2 (1,5) 
 1990-2008 19 7.1 (4.5,11.2) 8 (5,14) 10 6.7 (3.6,12.5) 4 (2,9) 5 4.9 (2.0,11.7) 2 (1,6) 5 10.7 (4.5,25.8) 2 (1,6) 
 Ptrend*  <0.001 (0.30) <0.001 (0.53)  <0.001 (0.83) <0.001 (0.77)  <0.001 (0.37) <0.001 (0.44)  <0.001 (0.05) 0.23 (0.06) 
Attained  0-20 24 14.8 (9.9,22.1) 5 (4,8) 16 18.7 (11.4,30.5) 4 (2,6) 13 16.5 (9.6,28.3) 3 (2,5) 3 44.3 (14.3,137.3) 1 (0,2) 
Age (yrs) 20-29 66 9.3 (7.3,11.9) 14 (11,18) 28 6.4 (4.4,9.3) 6 (4,9) 20 6.7 (4.3,10.4) 4 (2,7) 8 5.8 (2.9,11.6) 2 (1,4) 
 30-39 107 6.0 (5.0,7.3) 34 (27,43) 52 4.9 (3.7,6.4) 16 (11,22) 35 5.5 (3.9,7.6) 11 (7,16) 17 4.0 (2.5,6.5) 5 (3,9) 
 40-49 124 3.7 (3.1,4.5) 75 (59,96) 65 3.4 (2.7,4.4) 38 (27,54) 48 4.6 (3.4,6.0) 31 (22,45) 17 2.0 (1.2,3.2) 7 (3,18) 
 50+ 106 1.6 (1.4,2.0) 79 (48,129) 53 1.4 (1.1,1.8) 29 (12,74) 28 1.3 (0.9,1.9) 13 (3,59) 25 1.5 (1.0,2.2) 16 (5,52) 
  Ptrend*  <0.001 (<0.001) <0.001 (<0.001)  <0.001 (<0.001)  <0.001 (<0.001)  <0.001 (<0.001) <0.001 (<0.001)  <0.001 (0.03) <0.001 (<0.001) 
Type of  leukaemia 30 3.3 (2.3,4.7) 8 (5,14) 12 2.2 (1.2,3.8) 3 (1,7) 10 3.0 (1.6,5.6) 3 (1,7) 2 0.9 (0.2,3.6) 0 
childhood Hodgkin lymphoma 85 7.3 (5.9,9.0) 75 (59,96) 46 6.9 (5.2,9.2) 40 (29,57) 31 8.2 (5.8,11.6) 28 (19,42) 15 5.2 (3.1,8.6) 12 (7,23) 
cancer NHL 26 3.5 (2.4,5.1) 30 (18,52) 18 4.2 (2.6,6.7) 22 (12,41) 13 5.3 (3.1,9.2) 17 (9,34) 5 2.7 (1.1,6.5) 5 (1,21) 
 CNS tumour 60 2.0 (1.5,2.5) 11 (7,19) 36 2.0 (1.5,2.8) 7 (4,13) 21 2.1 (1.3,3.2) 4 (2,9) 15 2.0 (1.2,3.3) 3 (1,8) 
 neuroblastoma 10 3.2 (1.7,5.9) 11 (5,27) 5 2.7 (1.1,6.5) 5 (1,21) 3 2.8 (0.9,8.8) 3 (1,18) 2 2.5 (0.6,10.2) 2 (0,19) 
 retinoblastoma 13 1.8 (1.0,3.1) 8 (2,28) 7 1.6 (0.8,3.4) 4 (1,26) 5 2.0 (0.9,4.9) 4 (1,20) 2 1.1 (0.3,4.3) 0 
 Wilms Tumour 77 12.1 (9.6,15.1) 65 (51,83) 26 6.8 (4.6,10.0) 20 (13,32) 22 10.0 (6.6,15.2) 18 (11,29) 4 2.5 (0.9,6.6) 2 (0,11) 
 bone sarcoma 14 1.6 (0.9,2.6) 9 (2,38) 4 0.8 (0.3,2.1) 0 2 0.7 (0.2,2.7) 0 2 0.9 (0.2,3.6) 0 
 soft-tissue sarcoma 43 3.6 (2.7,4.8) 34 (22,51) 25 3.6 (2.4,5.3) 20 (11,34) 15 3.8 (2.3,6.2) 12 (6,24) 10 3.3 (1.8,6.2) 8 (3,18) 
 gonadal testis 10 4.2 (2.3,7.8) 29 (13,64) 4 3.1 (1.2,8.3) 10 (2,43) 3 4.2 (1.3,12.9) 9 (2,38) 1 1.8 (0.2,12.6) 2 (0,148) 
 gonadal ovary 17 4.9 (3.0,7.9) 63 (34,114) 10 4.6 (2.5,8.5) 36 (16,80) 5 3.8 (1.6,9.1) 17 (5,56) 5 5.8 (2.4,13.9) 19 (7,55) 
 other 35 1.8 (1.3,2.5) 11 (5,24) 17 1.5 (0.9,2.4) 4 (1,17) 11 1.6 (0.9,3.0) 3 (1,14) 6 1.3 (0.6,2.8) 1 (0,39) 
 not classifiable 7 2.8 (1.3,5.9) 38 (12,120) 4 3.3 (1.3,8.9) 24 (6,96) 3 4.8 (1.6,15.0) 20 (5,84) 1 1.7 (0.2,12.2) 4 (0,379) 
 Pheterogeneity*  <0.001 (<0.001) <0.001 (<0.001)  <0.001 (<0.001) <0.001 (<0.001)  <0.001 (<0.001) <0.001 (<0.001)  0.09 (0.01) 0.01 (0.01) 
* P-values in brackets refer to P-value derived from multivariable Poisson regression; O=observed number 
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Table 3 (continued). Standardised incidence ratios and absolute excess risks for subsequent liver, stomach and pancreas cancer. 
  liver stomach pancreas 
Factor level O SIR (95%CI) AER (95%CI) O SIR (95%CI) AER (95%CI) O SIR (95%CI) AER (95%CI) 
Overall All combined 62 8.1 (6.2,10.3) 4 (3,6) 48 2.9 (2.1,3.9) 2 (2,4) 44 3.2 (2.3,4.2) 2 (2,3) 
Sex Male 38 7.3 (5.3,1) 5 (3,7) 30 2.9 (2.0,4.2) 3 (2,5) 27 3.5 (2.4,5.1) 3 (2,5)  
Female 24 9.7 (6.5,14.4) 4 (2,6) 18 2.9 (1.8,4.6) 2 (1,4) 17 2.9 (1.8,4.6) 2 (1,4)  
Pheterogeneity*  0.29 (0.77) 0.33 (0.14)  0.96 (0.77) 0.40 (0.62)  0.54 (0.81) 0.36 (0.24) 
Age at  0-4 22 14.1 (9.3,21.4) 5 (3,7) 9 3.3 (1.7,6.4) 1 (1,4) 12 5.5 (3.1,9.7) 2 (1,4) 
diagnosis  5-9 14 11.3 (6.7,19.1) 5 (3,8) 4 1.7 (0.6,4.6) 1 (0,6) 7 3.8 (1.8,8.0) 2 (1,5) 
(yrs) 10-14 7 4.6 (2.2,9.6) 3 (1,7) 8 2.5 (1.3,5.0) 2 (1,7) 9 3.4 (1.8,6.5) 3 (1,8) 
 15-19 19 5.7 (3.6,8.9) 5 (3,8) 27 3.3 (2.2,4.8) 6 (3,10) 16 2.3 (1.4,3.8) 3 (1,6) 
 Ptrend*  <0.001 (0.59) 0.66 (0.70)  0.66 (0.82) 0.01 (0.19)  0.02 (0.34) 0.64 (0.62) 
Era of  <1970 29 6.2 (4.3,8.9) 8 (5,12) 17 1.6 (1.0,2.6) 2 (1,7) 20 2.0 (1.3,3.1) 3 (1,8) 
diagnosis 1970-1979 20 11.4 (7.4,17.7) 5 (3,8) 16 4.4 (2.7,7.1) 3 (2,7) 17 6.5 (4.0,10.5) 4 (2,7) 
 1980-1989 9 9.5 (4.9,18.2) 2 (1,4) 12 6.6 (3.7,11.6) 3 (1,5) 6 6.4 (2.9,14.3) 1 (0,3) 
  1990-2008 4 14.2 (5.3,37.9) 2 (1,5) 3 7.1 (2.3,22.0) 1 (0,5) 1 5.6 (0.8,39.7) 0 (0,4) 
 Ptrend*  0.06 (0.77) <0.001 (0.59)  <0.001 (0.04) 0.44 (0.46)  <0.001 (0.23) 0.02 (0.93) 
Attained  0-19 5 13.8 (5.7,33.0) 1 (0,3) 1 8.7 (1.2,61.8) 0 (0,2) 1 9.9 (1.4,70.2) 0 (0,2) 
Age (yrs) 20-29 13 19.8 (11.5,34.1) 3 (2,5) 8 6.6 (3.3,13.1) 2 (1,4) 5 12.4 (5.2,29.8) 1 (0,3) 
 30-39 13 12.6 (7.3,21.6) 5 (3,8) 15 4.8 (2.9,7.9) 5 (2,9) 11 7.8 (4.3,14.1) 4 (2,7) 
 40+ 31 5.5 (3.9,7.8) 15 (10,23) 24 2.0 (1.3,3.0) 7 (3,15) 27 2.3 (1.6,3.4) 9 (5,17) 
  Ptrend*  <0.001 (0.06) <0.001 (<0.001)  <0.001 (0.08) <0.001 (<0.001)  <0.001 (0.03) <0.001 (<0.001) 
Type of  leukaemia 5 7.4 (3.1,17.7) 2 (1,5) 1 0.8 (0.1,5.8) 0 2 2.6 (0.6,10.4) 0 (0,5) 
childhood Hodgkin lymphoma 6 8.0 (3.6,17.9) 5 (2,13) 14 8.5 (5.0,14.3) 13 (7,23) 9 7.1 (3.7,13.7) 8 (4,17) 
cancer NHL 1 2.2 (0.3,15.5) 1 (0,33) 0  0 0 3 3.7 (1.2,11.5) 4 (1,17) 
 CNS tumour 10 5.5 (3.0,10.3) 3 (1,7) 4 1.0 (0.4,2.7) 0 4 1.2 (0.4,3.2) 0 (0,103) 
 neuroblastoma 2 8.7 (2.2,34.8) 3 (1,14) 1 2.6 (0.4,18.1) 1 (0,25) 0  0 0 
 retinoblastoma 2 4.5 (1.1,18.1) 2 (0,13) 1 1.2 (0.2,8.2) 0 1 1.3 (0.2,9.2) 0 
 Wilms Tumour 19 41.0 (26.2,64.3) 17 (11,27) 7 8.8 (4.2,18.4) 6 (2,13) 11 16.9 (9.4,30.5) 10 (5,18) 
 bone Sarcoma 0  0 0 8 6.7 (3.4,13.4) 12 (5,27) 1 1.0 (0.1,6.8) 0  
 soft-tissue sarcoma 7 9.5 (4.5,19.9) 7 (3,16) 2 1.3 (0.3,5.1) 0 (0,268) 4 2.9 (1.1,7.8) 3 (1,13) 
 gonadal testis 2 11.2 (2.8,44.9) 7 (1,31) 5 6.5 (2.7,15.7) 9 (3,25) 2 7.9 (2.0,31.6) 7 (1,32) 
 gonadal ovary 3 19.8 (6.4,61.4) 13 (4,43) 4 1.5 (0.6,4.1) 1 (0,17) 0  0 0 
 other 4 3.7 (1.4,9.7) 2 (1,8) 1 2.0 (0.3,14.5) 4 (0,202) 7 3.0 (1.4,6.3) 3 (1,10) 
 not classifiable 1 7.0 (1.0,49.8) 7 (1,71) 1 0.8 (0.1,5.8) 0 0  0 0 
 Pheterogeneity*  0.001 (<0.001) <0.001 (<0.001)  <0.001 (<0.001) <0.001 (<0.001)  <0.001 (<0.001) <0.001 (<0.001) 
*P-values in brackets refer to P-value derived from multivariable Poisson regression; O=observed number 
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Number at risk 20 yrs 30 yrs 40 yrs 50 yrs 55 yrs 60 yrs 
All survivors  54041 35157 17995 7025 3943 2004 
Hodgkin lymphoma 5497 3500 1852 661 340 158 
Non-Hodgkin lymphoma 2828 1882 945 366 230 126 
CNS tumour 11139 7192 4005 1823 1042 546 
Wilms tumour 3637 2522 1239 373 172 71 
Soft-tissue sarcoma 3661 2506 1456 637 411 223 
       
 
 
